{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-23-003163","form_type":"8-K","ticker":null,"cik":"0001708331","company_name":"Virpax Pharmaceuticals, Inc.","filed_at":"2023-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.126460+00:00","generated_at":"2026-06-10T01:42:40.339104+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Virpax gets Nasdaq extension to April 2024 for minimum bid compliance","bullets":["Received 180-day extension from Nasdaq to April 8, 2024 to meet $1.00 minimum bid price.","Previously failed to regain compliance by Oct 9, 2023 after initial April 10, 2023 notice.","Must maintain bid price of at least $1.00 for ten consecutive business days to comply.","Considering options including reverse stock split to maintain Nasdaq listing.","Stock continues trading on Nasdaq Capital Market under symbol VRPX with no immediate impact."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-23-003163","json":"https://secwatch.observer/filing/0001013762-23-003163.json","markdown":"https://secwatch.observer/filing/0001013762-23-003163.md","text":"https://secwatch.observer/filing/0001013762-23-003163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708331/000101376223003163/0001013762-23-003163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708331/000101376223003163/ea186627-8k_virpaxpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:42:40.339104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de845520c74a7e5beddb8a7e091ad05fb7153d2f","claim":"Virpax Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"October 10, 2023, the Company received written notification from Nasdaq granting the Company’s request for a 180-day extension to regain compliance with Nasdaq Listing Rule 5550(a)(2). Compliance may be achieved if at any time prior to April 8, 2024 the closing bid price of the Company’s common stock is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will notify the Company that it has regained compliance with the Minimum Bid Price Requirement and the matter will be closed; however, Nasdaq has discretion to require the Company to maintain a bid price of $1.00 for a period","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000101376223003163/0001013762-23-003163-index.htm","confidence":0.99,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}